BY MARKETWIRE
-
Demant ready with new AI hearing aids in Q1
The brand-new AI listening device will certainly be dispersed throughout every one of its brand names, according to the business’s yearly record.
-
Novo Nordisk’s forecast for 2025 should provide relief, Sydbank says
Sydbank expert Søren Løntoft Hansen keeps in mind a number of strong check in Novo Nordisk’s yearly record.
-
Lundbeck Chair to step down at annual general meeting
The outward bound chairman has actually belonged to the Lundbeck board for greater than a years.
-
Novo Nordisk boosts Wegovy starter dose supply to the US
The Danish team enhances Wegovy manufacturing, preparing even more starter dosages for the United States market to enhance shipments after a duration of manufacturing restrictions …
-
WS Audiology’s growth slows in first quarter
Q1 profits in the very first quarter of the staggered 2024/25 totaled up to EUR 670m.
-
Novo Nordisk’s hemophilia drug is well-tolerated in children, interim analysis shows
The research study revealed that the investigational Mim8 was well-tolerated and effective in kids with the blood problem Hemophilia A.
-
Bristol-Myers Squibb stock falls due to weak 2025 outlook
Regardless of better-than-expected outcomes, capitalists are a lot more worried regarding Bristol Myers Squibb’s unsatisfactory projections.
-
Eli Lilly’s Q4 earnings outperform analyst estimates
Amongst Eli Lilly’s very successful medicines, sales of the diabetes mellitus 2 medicine Mounjaro enhanced by 60% in the 4th quarter.
-
Coloplast CEO: German launch of ostomy solution delayed
Presently, just the UK and German markets remain in Coloplast’s views when it pertains to the most effective markets for the ostomy remedy Heylo.
-
CHMP approves cancer drug from Genmab and Pfizer
With the choice, the best way is kind of paved for a closing approval.
